Skip to main content
. 2019 Apr 8;18:47. doi: 10.1186/s12933-019-0853-x

Fig. 2.

Fig. 2

Ranking of anti-diabetic agents ordered by their respective probability to be the best treatment for heart failure endpoints. SGLT2i sodium-glucoseco-transporter 2 inhibitors, GLP1ra glucagon-like peptide-1 receptor agonists, DPP4i dipeptidyl peptidase 4 inhibitors, TZD thiazolidinediones, MET metformin, SU sulfonylureas, INS insulin, PLA placebo